Key Takeaways
- • Alexandria Real Estate Equities has withdrawn from a joint venture with Prologis for a life science campus development project in South San Francisco at 100 East Grand Avenue, announced in October 2022.
- • The project had secured regulatory approval earlier in October 2022, shortly before Alexandria's decision to exit the partnership.
- • Alexandria recorded a $30–$38 million impairment charge in connection with the withdrawal from the venture.
- • The life science campus project represents a significant real estate development in the San Francisco Bay Area's competitive biotech facilities market, with expected capital contributions of $1.3 billion from joint venture partners through 2026 for construction.
Summary
Alexandria Real Estate Equities, the Pasadena-based life science facilities REIT, has terminated its joint venture partnership with Prologis for a mixed-use life science campus in South San Francisco. The project, located at 100 East Grand Avenue, had been announced the prior year and received municipal approval earlier in October 2022 before Alexandria's withdrawal.
The exit carries a material financial cost for Alexandria. The company recorded an impairment charge of between $30 million and $38 million to unwind its stake in the unconsolidated joint venture, reflecting the write-down of its investment in the partnership. The timing of the withdrawal—occurring shortly after project approval—suggests Alexandria reassessed the venture's strategic or financial viability following regulatory clearance.
The South San Francisco life science development was positioned as a substantial capital-intensive undertaking, with existing venture partners expected to contribute approximately $1.3 billion in total capital from the third quarter of 2023 through 2026 to fund construction. Such capital-heavy projects are typical in the life science real estate sector, where specialized laboratory and office infrastructure commands significant upfront investment. Alexandria's decision to exit indicates either a shift in the company's portfolio strategy, concerns about project economics, or changed market conditions in Bay Area life science real estate that prompted management to reallocate capital and resources elsewhere.
The withdrawal leaves Prologis as the remaining partner to navigate the project forward, representing a strategic divergence between two major players in the real estate investment sector as market conditions evolved in late 2022.
The exit carries a material financial cost for Alexandria. The company recorded an impairment charge of between $30 million and $38 million to unwind its stake in the unconsolidated joint venture, reflecting the write-down of its investment in the partnership. The timing of the withdrawal—occurring shortly after project approval—suggests Alexandria reassessed the venture's strategic or financial viability following regulatory clearance.
The South San Francisco life science development was positioned as a substantial capital-intensive undertaking, with existing venture partners expected to contribute approximately $1.3 billion in total capital from the third quarter of 2023 through 2026 to fund construction. Such capital-heavy projects are typical in the life science real estate sector, where specialized laboratory and office infrastructure commands significant upfront investment. Alexandria's decision to exit indicates either a shift in the company's portfolio strategy, concerns about project economics, or changed market conditions in Bay Area life science real estate that prompted management to reallocate capital and resources elsewhere.
The withdrawal leaves Prologis as the remaining partner to navigate the project forward, representing a strategic divergence between two major players in the real estate investment sector as market conditions evolved in late 2022.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.